Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Net Income (2021 - 2025)

Historic Net Income for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$31.5 million.

  • Aligos Therapeutics' Net Income fell 6375.2% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year decrease of 1235.69%. This contributed to the annual value of -$131.2 million for FY2024, which is 4964.93% down from last year.
  • Latest data reveals that Aligos Therapeutics reported Net Income of -$31.5 million as of Q3 2025, which was down 6375.2% from -$15.9 million recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Net Income peaked at $43.1 million during Q1 2025, and registered a low of -$82.1 million during Q4 2024.
  • Over the past 5 years, Aligos Therapeutics' median Net Income value was -$23.0 million (recorded in 2023), while the average stood at -$23.6 million.
  • The largest annual percentage gain for Aligos Therapeutics' Net Income in the last 5 years was 22359.23% (2025), contrasted with its biggest fall of 41343.61% (2025).
  • Quarter analysis of 5 years shows Aligos Therapeutics' Net Income stood at -$37.7 million in 2021, then skyrocketed by 41.97% to -$21.9 million in 2022, then decreased by 27.44% to -$27.9 million in 2023, then crashed by 194.53% to -$82.1 million in 2024, then skyrocketed by 61.61% to -$31.5 million in 2025.
  • Its last three reported values are -$31.5 million in Q3 2025, -$15.9 million for Q2 2025, and $43.1 million during Q1 2025.